Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05369832 · ClinicalTrials.gov registry record · Phase 4
An Open-label Study of Ozanimod in Moderate to Severe Ulcerative Colitis in Clinical Practice
A Phase 4 study, sponsored by Bristol-Myers Squibb.
- Terminated
- Registry status
- Phase 4
- Development phase
- 139
- Enrollment target
NCT05369832: Clinical Trial Phase 4 study, sponsored by Bristol-Myers Squibb.
NCT05369832 is a Phase 4 study that was terminated before completion, run by Bristol-Myers Squibb. The registered enrollment target is 139 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (73% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05369832, a Phase 4 study, was terminated before completion, sponsored by Bristol-Myers Squibb.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 139 participants
- Enrollment target
Study Summary
The purpose of this study is to explore the safety, efficacy, effects on quality of life (QOL), and biomarker response of ozanimod in participants with moderate to severely active ulcerative colitis (UC) in clinical practice.
Primary Outcome
Clinical response is defined as meeting all of the following improvements from baseline in the Modified Mayo Score: * Decrease from baseline ≥ 2 points, * Decrease from baseline ≥ 35%, * Decrease from baseline in the Rectal Bleeding (RB) subscore ≥ 1 point or absolute RB subscore ≤ 1 The Modified Mayo Score is a tool that helps doctors measure how active ulcerative colitis is. It combines three components: * Stool Frequency (SF): scored 0-3 (higher score = more frequent stools), * Rectal Blee
Interventions
- DRUG Ozanimod
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 139 participants |
| Start Date | 2022-12-16 |
| Est. Completion | 2025-04-11 |
| Phase | Phase 4 |
Why NCT05369832 stopped before completion
NCT05369832 is an interventional study that assigns participants to a tested intervention. The registered 139 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (73% lower).
The record links to 0 conditions, and to 1 intervention - of which Ozanimod is the first listed.
NCT05369832 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05369832 about?
NCT05369832 is a clinical study titled "An Open-label Study of Ozanimod in Moderate to Severe Ulcerative Colitis in Clinical Practice". The purpose of this study is to explore the safety, efficacy, effects on quality of life (QOL), and biomarker response of ozanimod in participants with moderate to severely active ulcerative colitis (UC) in clinical practice.
What is the current status of trial NCT05369832?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 139 participants. The study started on 2022-12-16. Estimated completion is 2025-04-11.
What interventions are being tested in trial NCT05369832?
The interventions under investigation include: Ozanimod (DRUG).
Who is sponsoring clinical trial NCT05369832?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05369832's enrollment target sits among peer trials
139 593rd of 2000 higher than 1,408 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05645380 · 139 participants · Phase 2
Neoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBC
- NCT06239272 · 139 participants · Phase 1
NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
- NCT06252220 · 139 participants · Phase 1
First in Human Study in Subjects With Obesity, But Otherwise Healthy
- NCT06537128 · 139 participants · NA
Internet-delivered Cognitive-Behavioral Therapy for Adolescents With Autism and Anxiety
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI